Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: A prospective study

Inflammation

Volumn 35, Issue 1, 2012, Pages 221-229

  Fourie, Carla M T ^a   Van Rooyen, Johannes M ^a   Kruger, Annamarie ^a   Olsen, Michael H ^b   Eugen Olsen, Jesper ^c   Schutte, Rudolph ^a   Schutte, Aletta E ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antiretroviral therapy; Black South Africans; Lipodystrophy; suPAR, HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; UROKINASE RECEPTOR;

ABDOMINAL FAT; ADULT; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PATIENT ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SOUTH AFRICA; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOUTH AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84859435997     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-011-9308-6     Document Type: Article

References (31)

1. Andersen, O., J. Eugen-Olsen, K. Kofoed, J. Iversen, and S.B. Haugaard. 2008. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. Journal of Medical Virology 80: 209-216.
2. Plesner, T., N. Behrendt, and M. Ploug. 1997. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15: 398-408. (Pubitemid 27513714)
3. Sidenius, N., C.F. Sier, H. Ullum, B.K. Pedersen, A.C. Lepri, F. Blasi, and J. Eugen-Olsen. 2000. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96: 4091-4095.
4. Ostrowski, S.R., T.L. Katzenstein, T. Piironen, J. Gerstoft, B.K. Pedersen, and H. Ullum. 2004. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 35: 337-342. (Pubitemid 38332793)
5. Ledergerber, B., M. Egger, M. Opravil, A. Telenti, B. Hirschel, M. Battegay, P. Vernazza, P. Sudre, M. Flepp, H. Furrer, P. Francioli, and R. Weber. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353: 863-868. (Pubitemid 29126872)
6. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B.H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360. (Pubitemid 34734202)
7. Freire, E. 2006. Overcoming HIV-1 resistance to protease inhibitors. Drug Discovery 3(2): 281-286. (Pubitemid 44356304)
8. Riddler, S.A., E. Smit, S.R. Cole, R. Li, J.S. Chmiel, A. Dobs, F. Palella, B. Visscher, R. Evans, and L.A. Kingsley. 2003. Impact of HIV infection and HAART on serum lipids in men. JAMA 289: 2978-2982. (Pubitemid 37430100)
9. Carr, A., and D.A. Cooper. 1998. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. The New England Journal of Medicine 339: 1296. (Pubitemid 28496196)
10. Grinspoon, S., and A. Carr. 2005. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. The New England Journal of Medicine 352: 48-62. (Pubitemid 40075680)
11. Stankov, M. V., and G. M. Behrens. 2010. Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients. Curr. Pharm. In press.
12. Constans, J., and C. Conri. 2006. Circulating markers of endothelial function in cardiovascular disease. Clinica Chimica Acta 368: 33-47. (Pubitemid 43792418)
13. Hsue, P.Y., J.C. Lo, A. Franklin, A.F. Bolger, J.N. Martin, S.G. Deeks, and D.D. Waters. 2004. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109: 1603-1608. (Pubitemid 38451715)
14. Glazier, J.J., J.R. Spears, and M.C. Murphy. 2006. Interventional approach to recurrent myocardial infarction in HIV-1 infection. Journal of Interventional Cardiology 19: 93-98.
15. Friis-Moller, N., P. Reiss, C.A. Sabin, R. Weber, A. Monforte, W. El-Sadr, R. Thiebaut, S. De Wit, O. Kirk, E. Fontas, M.G. Law, A. Phillips, and J.D. Lundgren. 2007. Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine 356: 1723-1735. (Pubitemid 46658704)
16. Andersen, O., J. Eugen-Olsen, K. Kofoed, J. Iversen, and S.B. Haugaard. 2008. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART. The Journal of Infection 57: 55-63.
17. Pawlak, K., D. Pawlak, and M. Mysliwiec. 2007. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Thrombosis Research 120: 871-876. (Pubitemid 47418233)
18. Pawlak, K., M. Mysliwiec, and D. Pawlak. 2008. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thrombosis Research 122: 328-335. (Pubitemid 351888889)
19. UNAIDS. 2008. Sub-Saharan Africa. Aids epidemic update. Regional Summary. Assessed at http://data.unaids.org/pub/Report/2008/jc1526-epibriefs-ssafrica- en.pdf on 31 March 2010.
20. Forsyth, B., A. Vandormael, T. Kershaw, and J. Grobbelaar. 2008. The political context of AIDS-related stigma and knowledge in a South African township community. SAHARA Journal 5: 74-82.
21. Herbst, A.J., G.S. Cooke, T. Barnighausen, A. KanyKany, F. Tanser, and M.L. Newell. 2009. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bulletin of the World Health Organization 87: 754-762.
22. Teo, K., C.K. Chow, M. Vaz, S. Rangarajan, and S. Yusuf. 2009. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic non-communicable diseases in low-, middle-, and high-income countries. American Heart Journal 158: 1-7.
23. Krain, A., and D.W. Fitzgerald. 2005. HIV antiretroviral therapy in resource-limited settings: experiences from Haiti. Curr HIV/AIDS Rep 2: 98-104.
24. Kruger, A., M. Greeff, M. Watson, and C. Fourie. 2009. Health care seeking behaviour of newly diagnosed HIV infected people from rural and urban communities in the North West Province of South Africa. Afr J Nurs 11(2): 28-45.
25. Greeff, M., and R. Phetlhu. 2007. The meaning and effect of HIV/AIDS stigma for people living with AIDS and nurses involved in their care in the North West Province, South Africa. Curationis 30: 12-23.
26. International Society for the Advancement of Kinanthropometry (ISAK). 2001. International standards for anthropometric assessment. Adelaide: National Library of Australia. P133.
27. Johnson, R., P. McNutt, S. MacMahon, and R. Robson. 1997. Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis. Clinical Chemistry 43: 2183-2184. (Pubitemid 27497820)
28. Peeters, M. 2001. The genetic variability of HIV-1 and its implications. Transfusion Clinique et Biologique 8: 222-225. (Pubitemid 32672977)
29. Jacobs, G.B., C. de Beer, J.E. Fincham, V. Adams, M.A. Dhansay, E.J. van Rensburg, and S. Engelbrecht. 2006. Serotyping and genotyping of HIV-1 infection in residents of Khayelitsha, Cape Town, South Africa. Journal of Medical Virology 78: 1529-1536.
30. Domingo, P., M.C. Cabeza, A. Pruvost, J. Salazar, M.M. Gutierrez, M.G. Mateo, J.C. Domingo, I. Fernandez, F. Villarroya, J. Munoz, F. Vidal, and M. Baiget. 2010. Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clinical Infectious Diseases 50: 1033-1040.
31. Lichtenstein, K.A., D.J. Ward, A.C. Moorman, K.M. Delaney, B. Young, F.J. Palella, P.H. Rhodes, K.C. Wood, and S.D. Holmberg. 2001. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15: 1389-1398. (Pubitemid 32662290)